தி ஜான்சன் மருந்து நிறுவனங்கள் ஆஃப் ஜான்சன் ஆம்ப் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தி ஜான்சன் மருந்து நிறுவனங்கள் ஆஃப் ஜான்சன் ஆம்ப். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தி ஜான்சன் மருந்து நிறுவனங்கள் ஆஃப் ஜான்சன் ஆம்ப் Today - Breaking & Trending Today

New Phase 3 Data Show First-in-Class TREMFYA® (guselkumab) Achieved Complete Skin Clearance and Favorable Joint Efficacy in Adult Patients with Active Psoriatic Arthritis (PsA) Through Two Years


Share this article
SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/
 The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2
a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA
® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112).
1,2 These findings also confirmed that the robust efficacy TREMFYA demonstrated in patients at Week 24 on physical function, physical aspects of health-related quality of life, and resolution of enthesitis
b and dactylitis
1-8 In addition, the extent of radiographic progression
d was studied through two years. These data will be presented virtually in abstract, poster, and video form during the Innovations in Dermatology: Virtual Spring Conference, March 16–20, 2021. ....

United States , University Of Washington , Spring House , British Columbia , Jennifer Mcintyre , Alyssa Johnsen , Philipj Mease , Christopher Delorefice , Bridget Kimmel , Zismand Comorbidities , American College Of Rheumatology , Department Of Medicine Division Rheumatology , Janssen Research Development , Janssen Pharmaceutical Companies , Health Qual Life Outcomes , Janssen Pharmaceutical Companies Of Johnson , Everyday Health , National Psoriasis Foundation , Swedish Medical Center Providence St , None Of The Janssen Pharmaceutical Companies , Joseph Health , Drug Administration , Arthritis Research Therapy , Exchange Commission , Virtual Spring Conference , Swedish Medical ,

Janssen to Highlight Latest Research on Multiple Sclerosis at ACTRIMS Forum 2021


Janssen to Highlight Latest Research on Multiple Sclerosis at ACTRIMS Forum 2021
News provided by
Share this article
Share this article
TITUSVILLE, N.J., Feb. 24, 2021 /PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that its latest multiple sclerosis (MS) research will be presented at the 2021 Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum from February 25-27. Nine Janssen-sponsored data abstracts on MS research will be presented, including real-world evidence highlighting the impact of fatigue in U.S. adults with relapsing MS (RMS); a study assessing the impact of MS fatigue on work productivity and activity impairment; and cross-sectional analyses of both the economic and humanistic burden associated with fatigue in relapsing-remitting MS. ....

United States , Jennifer Mcintyre , Chris Delorefice , Bill Martin , Us National Health , Americas Committee For Treatment , Sclerosis Association Of America , National Multiple Sclerosis Society , Janssen Research Development , Janssen Pharmaceutical Companies , Janssen Pharmaceutical Companies Of Johnson , Research In Multiple Sclerosis , None Of The Janssen Pharmaceutical Companies , Drug Administration , Actelion Pharmaceuticals Ltd , Exchange Commission , Companies Of Johnson , Idorsia Pharmaceuticals Ltd , European Medicines Agency , Multiple Sclerosis , Global Therapeutic Area Head , Janssen Research , Data Presentations Include , Fatigue Status , Disease Activity , Fatigue Symptom ,